Media coverage about MEI Pharma (NASDAQ:MEIP) has been trending somewhat positive recently, according to Accern. The research group identifies negative and positive media coverage by monitoring more than twenty million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. MEI Pharma earned a news sentiment score of 0.10 on Accern’s scale. Accern also gave news articles about the company an impact score of 46.0578517893154 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the near future.
Here are some of the headlines that may have effected Accern Sentiment’s rankings:
- NEA Management Company, LLC Buys Surface Oncology Inc, MEI Pharma Inc, Tintri Inc, Sells CRISPR Therapeutics … (gurufocus.com)
- Analysts Expect MEI Pharma Inc (MEIP) to Post -$0.22 Earnings Per Share (americanbankingnews.com)
- MEI Pharma Inc (MEIP) COO David M. Urso Sells 9,500 Shares (americanbankingnews.com)
- Active Daily Watch List: PEDEVCO Corp. (PED), MEI Pharma, Inc. (MEIP) (newsregistrar.com)
MEIP has been the topic of a number of recent analyst reports. Wells Fargo & Co upgraded shares of MEI Pharma from a “market perform” rating to an “outperform” rating in a research note on Wednesday, June 6th. SunTrust Banks initiated coverage on shares of MEI Pharma in a research note on Friday, July 13th. They set a “buy” rating and a $12.00 price target on the stock. Cann restated a “buy” rating on shares of MEI Pharma in a research note on Monday, July 9th. ValuEngine upgraded shares of MEI Pharma from a “hold” rating to a “buy” rating in a research note on Wednesday, May 2nd. Finally, Zacks Investment Research upgraded shares of MEI Pharma from a “hold” rating to a “buy” rating and set a $5.00 price target on the stock in a research note on Wednesday, July 11th. One research analyst has rated the stock with a hold rating and seven have issued a buy rating to the company. The company presently has a consensus rating of “Buy” and an average price target of $7.42.
MEI Pharma (NASDAQ:MEIP) last released its quarterly earnings data on Wednesday, May 9th. The company reported ($0.16) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.24) by $0.08. The firm had revenue of $0.43 million for the quarter, compared to analyst estimates of $0.40 million. MEI Pharma had a negative net margin of 1,651.87% and a negative return on equity of 60.75%. analysts predict that MEI Pharma will post -0.81 earnings per share for the current fiscal year.
In other news, COO David M. Urso sold 9,500 shares of the stock in a transaction on Tuesday, August 7th. The shares were sold at an average price of $3.58, for a total value of $34,010.00. Following the sale, the chief operating officer now owns 33,606 shares in the company, valued at $120,309.48. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. 5.25% of the stock is owned by corporate insiders.
About MEI Pharma
MEI Pharma, Inc, an oncology company, focuses on the clinical development of drugs for the treatment of cancer. The company's clinical drug candidate includes Pracinostat, an orally available histone deacetylase inhibitor for the treatment of patients with acute myeloid leukemia and myelodysplastic syndrome.
Featured Story: Book Value Per Share – BVPS
Receive News & Ratings for MEI Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MEI Pharma and related companies with MarketBeat.com's FREE daily email newsletter.